How To Implement MRD Testing In Daily Practice
Suzanne Lentzsch, M.D., PhD Associate Professor of Medicine & Director of the Multiple Myeloma and Amyloidosis Service at Columbia University Medical Center. Discusses How To Implement MRD Testing In ... Author: imedex Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts

The potential of anti-amyloid antibodies to treat amyloidosis
Dr Suzanne Lentzsch, MD, PhD, of Columbia University, New York, NY, presents data from the latest clinical trials testing drugs for amyloidosis. Lentzsch reports on an ongoing study that compares the ... Author: VJHemOnc Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts

If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea
Ray Comenzo, MD, Tufts Medical Center, explains If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Earlier Diagnosis for Smoldering Multiple Myeloma or Monoclonal Gammopathy of Unknown Significance | At Risk of Progressing to Light-chain Amyloidosis
Ray Comenzo, MD, Tufts Medical Center, explains Earlier Diagnosis for SMM or MGUS | At Risk of Progressing to Light-chain Amyloidosis at ASCO 2018 Author: Annual-Meeting Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Treatment outcomes of elderly patients with AL Amyloidosis
Systemic amyloid light-chain (AL) amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly, but treatment and outcomes have not been systematical... Author: VJHemOnc Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Unmet needs in amyloidosis
A large contributing factor to outcome in amyloidosis is the stage of diagnosis. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the need to improve outcomes in pati... Author: VJHemOnc Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts

New antibody treatments for AL amyloidosis
This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on the horizon. In this interview, Giampaolo Merlini, MD, from the University of Pa... Author: VJHemOnc Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Biomarkers of amyloidosis
New insights into amyloid light-chain (AL) amyloidosis have emerged in recent years. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, gives an overview of the mechanisms behind... Author: VJHemOnc Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts

Final Analysis of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Pts with RR Amyloidosis
Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with RR AmyloidosisSuzanne Lentzsch, MD, PhDColumbia University Medical CenterNew York... Author: InternationalMyelomaFoundation Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Major breakthroughs in AL amyloidosis treatment from ASH 2017
Several major breakthroughs in the treatment of amyloid light-chain (AL) amyloidosis were presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. In th... Author: VJHemOnc Added: 01/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Upcoming amyloidosis clinical trial data to look forward to at ASH 2017
In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, talks to us about the most antic... Author: VJHemOnc Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts

An unmet need: reducing early death in amyloidosis
Around a quarter of new amyloidosis patients die within 6 months of diagnosis, and, despite large pharmacological and technological advancements, this statistic has not improved over the past three de... Author: VJHemOnc Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts

Game-changing drugs for amyloidosis treatment
There are two primary routes of therapy for amyloidosis: treating the underlying plasma cell dyscrasia, and clearing amyloid deposits. In this insightful interview, recorded at the Myeloma 2017 meetin... Author: VJHemOnc Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts

Exciting improvements in amyloidosis management and treatment
Key to the treatment of amyloidosis is being able to discern the severity of illness, so that the patient can be prescribed an appropriate therapy course. In this interview, Ashutosh Wechalekar, MBBS,... Author: VJHemOnc Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts

Amyloidosis Treatment Trends for 2017
Jason Valent, MD of Cleveland Clinic gives an overview of the current treatment trends for amyloidosis at the 58th ASH Annual Meeting in San Diego, CA. Author: ASHReport Added: 12/16/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 16, 2016 Category: Cancer & Oncology Source Type: podcasts

NEOD001 Set To Be Practice Changing for Amyloidosis
Jason Valent, MD of Cleveland Clinic discusses how new novel agents are changing the management of amyloidosis at the 58th ASH Annual Meeting in San Diego, CA. Author: ASHReport Added: 12/16/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 16, 2016 Category: Cancer & Oncology Source Type: podcasts

ASH Clinical News: Promising Cardiac and Renal Responses with NEOD001 in Patients with AL Amyloidosis
Morie Gertz, MD, talks to ASH Clinical News about the positive data from a phase I/II trial of the monoclonal antibody NEOD001 – a potentially disease-modifying agent for patients with AL amyloidosis ... Author: ash Added: 12/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 16, 2015 Category: Cancer & Oncology Source Type: podcasts

ASH 2015: Oral Doxycycline Improves Outcomes of Stage III Amyloidosis - a Matched Case Control Study
Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study Dr. Ashutosh Wechalekar National Amyloidosis Centre University College London London, United Kingdo... Author: InternationalMyelomaFoundation Added: 12/08/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 8, 2015 Category: Cancer & Oncology Source Type: podcasts

Should all myeloma patients be screened for amyloidosis?
In this week's video Dr. Brian Durie answers Laura Mooney's question about amyloidosis and if myeloma patients should be screened for it. Laura is the leader of the Staten Island Support Group. Bot... Author: MultipleMyeloma Added: 08/20/2015 (Source: Oncology Tube)
Source: Oncology Tube - August 21, 2015 Category: Cancer & Oncology Source Type: podcasts

Dr Rafael Fonseca at ASH 2014: MRD in myeloma and proteasome inhibition in amyloidosis
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis. In multiple myeloma, minimum residual di... Author: EMJ Added: 01/27/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 27, 2015 Category: Cancer & Oncology Source Type: podcasts

Cardiac Amyloidosis: The Great Imitator
Three Mayo experts explain the three main types of cardiac amyloidosis and dispel some myths about the diagnosis and treatment of this rare condition. (Source: Medscape Cardiology Podcast)
Source: Medscape Cardiology Podcast - September 8, 2014 Category: Cardiology Authors: Medscape Source Type: podcasts

Amyloidosis: Past, present, and future
This outstanding webcast of Lymphoma & Myeloma 2013, an International Congress on Hematologic Malignancies, includes experts presenting the current issues and clinical trial information in lymphom... Author: imedex Added: 01/07/2014 (Source: Oncology Tube)
Source: Oncology Tube - January 7, 2014 Category: Cancer & Oncology Source Type: podcasts